Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with significant unmet medical need, particularly in cardiovascular indications. The company’s portfolio centers on interleukin-1 inhibition therapies targeting inflammatory pathways in autoinflammatory and cardiovascular diseases. Its lead product, ARCALYST, is an interleukin-1α and interleukin-1β cytokine trap approved for multiple indications in the United States.

The company generates revenue primarily through the commercial sale of ARCALYST in the United States for approved indications including recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Kiniksa evenly splits profits on ARCALYST sales with Regeneron under their licensing agreement and also shares proceeds from out-licensing arrangements, such as the agreement with Huadong for the Asia Pacific region. Revenue is derived from product sales, milestone payments, and royalty streams from collaborative and licensing partnerships.

The company operates through the following segments:

• ARCALYST: This segment includes the commercialization and development of ARCALYST, an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is approved in the United States for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older, the treatment of CAPS including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome in adults and children 12 years and older, and the maintenance of remission in DIRA in adults and children weighing 10 kg or more. The product is distributed through a select network of specialty pharmacies in the United States.

• KPL-387: This segment focuses on the development of an investigational fully human immunoglobulin G2 monoclonal antibody that binds interleukin-1 receptor 1, inhibiting IL-1α- and IL-1β-mediated signaling. KPL-387 is being developed for the treatment of recurrent pericarditis with the potential for monthly subcutaneous self-administration using a liquid formulation. The company is currently conducting the Phase 2 dose-focusing portion of a Phase 2/3 clinical trial, with data expected in the second half of 2026.

• KPL-1161: This segment involves the preclinical development of an Fc-modified immunoglobulin G2 monoclonal antibody designed as a modified version of KPL-387 to have an increased drug half-life, potentially supporting quarterly subcutaneous dosing. KPL-1161 binds IL-1R1 to inhibit IL-1α- and IL-1β-mediated signaling. The company plans to initiate a Phase 1 first-in-human clinical trial by the end of 2026.

• Abiprubart: This segment covers the development of an investigational monoclonal antibody inhibitor of CD40-CD154 costimulatory interaction. Kiniksa holds an exclusive worldwide license to abiprubart from Beth Israel Deaconess Medical Center. The company previously announced a Phase 2b clinical trial in Sjögren’s Disease but announced plans in February 2025 to discontinue development in that indication and explore strategic alternatives for the asset.

Kiniksa holds a differentiated position in the biopharmaceutical industry as the first and only company with an FDA-approved therapy for recurrent pericarditis through ARCALYST. The company faces competition from other interleukin-1 pathway inhibitors in development, including anakinra, canakinumab, lutikizumab, goflikicept, and VTX2735, but maintains a competitive advantage through its dual IL-1α and IL-1β inhibition mechanism, which addresses limitations of IL-1β-only inhibitors in certain patient populations. Its pipeline of next-generation IL-1 inhibitors aims to improve dosing convenience and patient experience.

The company’s customer base consists primarily of patients suffering from recurrent pericarditis, CAPS, and DIRA, who are treated by specialists including cardiologists, rheumatologists, and immunologists. Kiniksa serves patients through a specialty pharmacy network in the United States and collaborates with healthcare providers, patient advocacy groups, and institutions such as The Mayo Clinic and Johns Hopkins University on clinical research initiatives.